Tactile Systems Technology Inc
NASDAQ:TCMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
US |
|
A
|
Advani Hotels and Resorts (India) Ltd
NSE:ADVANIHOTR
|
IN |
|
P
|
Plastikkart Akilli Kart Iletisim Sistemleri Sanayi ve Ticaret AS
IST:PKART.E
|
TR |
|
TPG Telecom Ltd
ASX:TPG
|
AU |
|
Malvern International PLC
LSE:MLVN
|
UK |
|
Ucommune International Ltd
NASDAQ:UK
|
US |
Tactile Systems Technology Inc
Tactile Systems Technology, Inc. is a medical technology company. The company is headquartered in Minneapolis, Minnesota and currently employs 988 full-time employees. The company went IPO on 2016-07-28. Its therapeutic focus is vascular disease, for treating lymphedema and chronic venous insufficiency. The company is a manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Its at-home Flexitouch system provides automated, at-home lymphatic drainage therapy. Its Flexitouch Plus system is an automated, programmable, pneumatic compression device (APCD), designed for the treatment of lymphedema in the home setting. Its Entre system is a pneumatic compression device used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company possesses a platform to deliver at-home healthcare solutions directly to patients throughout the United States.
Tactile Systems Technology, Inc. is a medical technology company. The company is headquartered in Minneapolis, Minnesota and currently employs 988 full-time employees. The company went IPO on 2016-07-28. Its therapeutic focus is vascular disease, for treating lymphedema and chronic venous insufficiency. The company is a manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Its at-home Flexitouch system provides automated, at-home lymphatic drainage therapy. Its Flexitouch Plus system is an automated, programmable, pneumatic compression device (APCD), designed for the treatment of lymphedema in the home setting. Its Entre system is a pneumatic compression device used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company possesses a platform to deliver at-home healthcare solutions directly to patients throughout the United States.
Strong Revenue Growth: Tactile Medical reported fourth quarter revenue of $103.6 million, up 21% year-over-year, and full year revenue of $329.5 million, a 12% increase from last year.
Margin Expansion: Full year gross margin improved by 190 basis points to 75.9%, with Q4 gross margin reaching 78.2%.
Profitability Gains: Adjusted EBITDA for the year rose 21% to $44.8 million, and Q4 adjusted EBITDA was $22 million versus $16.2 million a year ago.
Cash Generation & Capital Deployment: The company generated nearly $43 million in operating cash flow, repaid $26.3 million of debt, and repurchased $26.5 million in stock, ending the year with $83.4 million in cash and no borrowings.
2026 Guidance: Management expects 2026 revenue of $357–$365 million (8–11% growth), and adjusted EBITDA of $49–$51 million.
Regulatory Update: Guidance incorporates a short-term headwind from new Medicare prior authorization requirements, which may temporarily slow lymphedema market growth but is expected to normalize over time.
Strategic Acquisition: Tactile announced the acquisition of LymphaTech, expanding its digital measurement capabilities and supporting its evolution to a comprehensive lymphedema solutions provider.
